The city of Providence, Rhode Island, currently has 1 active clinical trials seeking participants for Ulcerative Colitis research studies.
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Between 18 years and 80 years
Trial Updated:
Locations: Gastroenterology Associates, Providence, Rhode Island
Conditions: Ulcerative Colitis, Crohn Disease